Post-Traumatic Stress Disorder (PTSD)

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
References & Research
Featured Videos

1. Overview

Post-Traumatic Stress Disorder (PTSD) is a severe psychiatric condition that develops in some individuals following exposure to a traumatic event involving actual or threatened death, serious injury, or sexual violence. The disorder is characterized by four distinct symptom clusters: intrusion symptoms (re-experiencing the trauma), persistent avoidance of trauma-related stimuli, negative alterations in cognition and mood, and marked alterations in arousal and reactivity. PTSD was first formally recognized as a distinct diagnosis in the DSM-III (1980), largely influenced by the psychological aftermath observed in Vietnam War veterans, although descriptions of trauma-related psychological disturbance date back centuries.

PTSD is classified under Trauma- and Stressor-Related Disorders in the DSM-5, representing a shift from its previous categorization among anxiety disorders. The condition can manifest at any age, including childhood, and may present acutely or with delayed onset (symptoms beginning more than six months after the traumatic event). The DSM-5 also recognizes a dissociative subtype, characterized by depersonalization or derealization symptoms, affecting approximately 10-30% of PTSD patients.

The disorder carries significant personal and societal burden, contributing to functional impairment across occupational, social, and interpersonal domains. PTSD frequently co-occurs with other psychiatric conditions, including major depressive disorder (in up to 50% of cases), substance use disorders, generalized anxiety disorder, and traumatic brain injury. Without appropriate treatment, PTSD can follow a chronic, relapsing course that substantially diminishes quality of life and increases mortality risk through both medical comorbidity and suicide.

2. Epidemiology

The lifetime prevalence of PTSD in the general U.S. population is approximately 6.1-7.8%, with 12-month prevalence estimated at 3.5-4.7% according to the National Comorbidity Survey Replication. Women are approximately twice as likely as men to develop PTSD, with lifetime prevalence rates of 10-12% for women versus 5-6% for men. This gender disparity persists even after controlling for trauma type and is thought to involve both biological factors (hormonal influences on fear conditioning) and differences in trauma exposure patterns.

Trauma exposure is remarkably common, with approximately 60-90% of adults experiencing at least one potentially traumatic event during their lifetime. However, only a minority of trauma-exposed individuals develop PTSD. Conditional probability of developing PTSD varies substantially by trauma type: sexual assault carries the highest risk at 30-50%, followed by combat exposure (10-30%), physical assault (20-25%), serious accidents (5-10%), and natural disasters (3-5%).

Military populations exhibit significantly elevated rates, with 11-20% of veterans of Operations Iraqi Freedom and Enduring Freedom meeting diagnostic criteria for PTSD. Among first responders, prevalence ranges from 7-37% depending on role and cumulative exposure. Globally, cross-national epidemiologic studies report lifetime PTSD prevalence ranging from 1.3% in Japan to 8.8% in Northern Ireland, reflecting variations in trauma exposure and cultural factors.

3. Pathophysiology

Fear Conditioning and Extinction

The core neurobiological model of PTSD centers on dysregulated fear learning. During trauma, the brain forms powerful associative memories linking environmental cues to threat. In PTSD, fear conditioning becomes pathologically enhanced while fear extinction (the process of learning that previously threatening cues are now safe) is impaired. This imbalance results in persistent fear responses to trauma-related stimuli and generalization of fear to neutral contexts. Pavlovian fear conditioning paradigms demonstrate that PTSD patients show enhanced acquisition of conditioned fear, resistance to extinction learning, and impaired extinction retention.

Key Brain Regions

Neuroimaging studies consistently identify a triad of brain regions showing functional abnormalities in PTSD. The amygdala demonstrates hyperactivation to threat-related stimuli, reflecting enhanced threat detection and fear processing. The medial prefrontal cortex (mPFC), particularly the ventromedial PFC and anterior cingulate cortex, shows reduced activation, corresponding to deficient top-down regulation of amygdala-driven fear responses. The hippocampus shows both functional hypoactivation and structural volume reduction (approximately 5-12% smaller in PTSD patients), contributing to impaired contextual processing of memories and difficulty distinguishing safe from threatening environments.

HPA Axis Dysregulation

PTSD is paradoxically associated with lower basal cortisol levels and enhanced negative feedback sensitivity of the hypothalamic-pituitary-adrenal (HPA) axis, contrasting with the hypercortisolism seen in major depression. PTSD patients demonstrate increased glucocorticoid receptor sensitivity, enhanced dexamethasone suppression, and elevated corticotropin-releasing hormone (CRH) levels in cerebrospinal fluid. This neuroendocrine profile may contribute to the heightened stress reactivity and exaggerated sympathetic nervous system activation characteristic of the disorder.

Neurotransmitter Systems

Multiple neurotransmitter systems are implicated in PTSD pathophysiology. The noradrenergic system shows hyperactivity, with elevated cerebrospinal fluid norepinephrine levels contributing to hyperarousal, exaggerated startle, and intrusive memories. Serotonergic dysfunction is evidenced by altered 5-HT1B receptor binding and reduced serotonin transporter availability. The GABAergic system shows reduced benzodiazepine receptor binding in cortical regions. Glutamatergic hyperactivation, particularly involving NMDA receptors, contributes to excitotoxicity and may mediate the neurotoxic effects of chronic stress on hippocampal neurons. The endocannabinoid system also shows dysregulation, with reduced anandamide levels and upregulated CB1 receptors.

4. Etiology and Risk Factors

Trauma-Related Factors

Interpersonal violence (sexual assault, combat, torture) carries higher PTSD risk than accidents or natural disasters
Trauma severity — dose-response relationship between trauma intensity, duration, and PTSD risk
Perceived life threat during the event is a stronger predictor than objective severity
Peritraumatic dissociation — dissociative experiences during the trauma strongly predict subsequent PTSD
Cumulative trauma exposure — repeated trauma increases risk in a dose-dependent fashion
Betrayal trauma — trauma perpetrated by trusted individuals (caregivers, partners) carries elevated risk

Pre-Traumatic Risk Factors

Prior psychiatric history — pre-existing depression, anxiety, or prior PTSD
Childhood adversity — abuse, neglect, and household dysfunction (ACEs)
Genetic vulnerability — heritability estimated at 30-40%; polymorphisms in FKBP5, SLC6A4 (serotonin transporter), and ADCYAP1R1 (PACAP receptor) genes
Neurocognitive factors — lower IQ and executive function deficits pre-trauma
Female sex — approximately 2x risk compared to males
Younger age at trauma exposure
Lower socioeconomic status and education

Post-Traumatic Factors

Lack of social support — the single strongest post-trauma predictor of PTSD
Additional life stressors following the trauma
Maladaptive coping strategies — avoidance, substance use, self-blame
Acute stress disorder — presence of ASD symptoms in the first month post-trauma

Epigenetic Factors

DNA methylation changes in stress-related genes (NR3C1, FKBP5) linked to PTSD risk
Intergenerational transmission of trauma-related epigenetic modifications observed in offspring of PTSD patients
MicroRNA dysregulation — altered expression of miR-138, miR-15a, and others in peripheral blood

5. Clinical Presentation

Intrusion Symptoms (Cluster B)

Patients experience involuntary, distressing re-experiencing of the traumatic event through intrusive memories, recurrent nightmares, flashbacks (dissociative reactions in which the individual feels or acts as if the event is recurring), and intense psychological distress or physiological reactivity upon exposure to internal or external cues resembling aspects of the trauma. Flashbacks may range from brief sensory intrusions to complete loss of awareness of present surroundings.

Avoidance Symptoms (Cluster C)

Persistent effortful avoidance of distressing memories, thoughts, or feelings associated with the trauma, and avoidance of external reminders (people, places, conversations, activities, objects, situations) that arouse such recollections. Avoidance may be behavioral (refusing to drive after an accident) or cognitive (inability to recall key aspects of the trauma).

Negative Alterations in Cognition and Mood (Cluster D)

This cluster includes persistent negative beliefs about oneself, others, or the world ("I am permanently damaged," "No one can be trusted"), distorted cognitions about the cause or consequences of the trauma leading to self-blame or blame of others, persistent negative emotional states (fear, horror, anger, guilt, shame), markedly diminished interest in significant activities, feelings of detachment or estrangement from others, and persistent inability to experience positive emotions (emotional numbing).

Alterations in Arousal and Reactivity (Cluster E)

Marked changes include irritable behavior and angry outbursts (with little or no provocation), reckless or self-destructive behavior, hypervigilance, exaggerated startle response, concentration difficulties, and sleep disturbance (difficulty falling or staying asleep, restless sleep). These symptoms reflect a persistent state of heightened threat detection and autonomic arousal.

Dissociative Subtype

The DSM-5 dissociative subtype is characterized by depersonalization (feeling detached from one's own mind or body, as if in a dream or as an outside observer) and/or derealization (experiencing surroundings as unreal, dreamlike, distant, or distorted). This subtype is associated with more severe trauma histories, greater functional impairment, and higher rates of comorbid disorders.

6. Diagnosis

DSM-5 Diagnostic Criteria

Diagnosis requires all of the following:

Criterion A: Exposure to actual or threatened death, serious injury, or sexual violence through direct experience, witnessing, learning about it happening to a close person, or repeated professional exposure to aversive details
Criterion B: At least 1 intrusion symptom
Criterion C: At least 1 avoidance symptom
Criterion D: At least 2 negative cognition/mood symptoms
Criterion E: At least 2 arousal/reactivity symptoms
Criterion F: Duration of symptoms >1 month
Criterion G: Clinically significant distress or functional impairment
Criterion H: Disturbance not attributable to substance effects or another medical condition

Screening Instruments

PTSD Checklist for DSM-5 (PCL-5) — 20-item self-report measure; scores range 0-80; cutoff score of 31-33 for probable PTSD diagnosis
Primary Care PTSD Screen (PC-PTSD-5) — 5-item screen designed for primary care settings; score ≥3 indicates need for further evaluation
Life Events Checklist for DSM-5 (LEC-5) — screens for potentially traumatic event exposure

Clinician-Administered Assessments

Clinician-Administered PTSD Scale (CAPS-5) — the gold standard structured diagnostic interview; 30-item assessment measuring frequency and intensity of each DSM-5 PTSD symptom
PTSD Symptom Scale Interview (PSS-I-5) — semi-structured interview assessing DSM-5 symptoms

Differential Diagnosis

Key conditions to differentiate include acute stress disorder (symptoms lasting 3 days to 1 month), adjustment disorders (subthreshold trauma or stressor), major depressive disorder, panic disorder, obsessive-compulsive disorder, dissociative disorders, traumatic brain injury, and personality disorders (particularly borderline personality disorder). Substance-induced symptoms and medical conditions (thyroid dysfunction, seizure disorders) must also be excluded.

7. Treatment

First-Line Psychotherapy

Trauma-focused psychotherapies are considered the most effective treatments for PTSD and are recommended as first-line by all major clinical practice guidelines:

Prolonged Exposure (PE) — involves imaginal revisiting of the trauma memory and in vivo exposure to avoided situations; typically 8-15 sessions of 90 minutes; effect sizes of d = 1.08-1.82
Cognitive Processing Therapy (CPT) — focuses on identifying and modifying maladaptive trauma-related cognitions ("stuck points"); 12 sessions; effect sizes of d = 1.09-1.40
Eye Movement Desensitization and Reprocessing (EMDR) — combines trauma memory processing with bilateral stimulation (typically horizontal eye movements); 8-12 sessions; effect sizes comparable to PE and CPT
Written Exposure Therapy (WET) — a brief 5-session protocol involving written narratives of the traumatic event with psychoeducation

Pharmacotherapy

First-line medications:

Sertraline (Zoloft) — SSRI; FDA-approved for PTSD; typical dose 50-200 mg/day; NNT approximately 11
Paroxetine (Paxil) — SSRI; FDA-approved for PTSD; typical dose 20-60 mg/day
Fluoxetine (Prozac) — SSRI; 20-60 mg/day; strong evidence base though not FDA-approved for PTSD
Venlafaxine (Effexor XR) — SNRI; 75-300 mg/day; comparable efficacy to SSRIs

Adjunctive and second-line medications:

Prazosin — alpha-1 adrenergic antagonist; 1-15 mg at bedtime; specifically targets trauma-related nightmares and sleep disruption
Mirtazapine (Remeron) — 15-45 mg/day; useful for comorbid insomnia and appetite loss
Topiramate — 25-400 mg/day; some evidence for hyperarousal and re-experiencing symptoms
Quetiapine — atypical antipsychotic; 25-300 mg/day; used adjunctively for treatment-resistant cases

Medications to avoid: Benzodiazepines are not recommended for PTSD treatment as they may interfere with fear extinction, worsen outcomes, and carry addiction risk. VA/DoD guidelines specifically recommend against their use.

Combination Treatment

Current evidence suggests that trauma-focused psychotherapy alone is generally preferred over medication alone, with combination treatment (psychotherapy plus pharmacotherapy) recommended for patients with severe symptoms, significant comorbidity, or partial response to monotherapy. The VA/DoD Clinical Practice Guidelines (2023) strongly recommend PE, CPT, or EMDR as first-line treatments, with pharmacotherapy as an alternative when trauma-focused psychotherapy is unavailable or declined.

Emerging Treatments

Stellate ganglion block (SGB) — injection of local anesthetic at the C6 vertebral level; targets the sympathetic nervous system; promising preliminary results
Accelerated resolution therapy — brief exposure-based treatment combining elements of EMDR and imaginal exposure
Virtual reality exposure therapy — immersive technology-enhanced exposure therapy, particularly studied in combat-related PTSD

8. Complications

Suicidality — PTSD patients have a 3-6 fold increased risk of suicide attempts; approximately 27% of PTSD patients report suicidal ideation
Substance use disorders — comorbid in 20-40% of cases; self-medication hypothesis; alcohol use disorder is most common
Major depressive disorder — co-occurs in approximately 50% of PTSD patients
Cardiovascular disease — PTSD independently increases risk of coronary heart disease, hypertension, and metabolic syndrome
Chronic pain syndromes — fibromyalgia, chronic headache, and musculoskeletal pain are significantly elevated
Autoimmune disorders — emerging evidence links PTSD to increased risk of rheumatoid arthritis, lupus, and inflammatory bowel disease
Neurocognitive decline — accelerated cognitive aging and increased risk of dementia
Interpersonal difficulties — relationship dysfunction, intimate partner violence, impaired parenting
Occupational impairment — higher rates of unemployment, disability, and reduced work productivity
Moral injury — persistent distress from acts that transgress moral beliefs, particularly in military and healthcare contexts

9. Prognosis

The natural course of PTSD is variable. Approximately 50% of adults with PTSD recover within 3-6 months without treatment, representing a natural resilience trajectory. However, approximately one-third of cases follow a chronic course persisting for years or decades if untreated. Delayed-onset PTSD, accounting for approximately 25% of cases, may not manifest until months or years after trauma exposure, often triggered by subsequent life stressors or additional trauma.

With evidence-based psychotherapy, approximately 50-60% of patients achieve clinically meaningful symptom reduction, and 30-50% achieve full remission by end of treatment. Treatment response rates are generally higher for civilian trauma (particularly sexual assault) compared to combat-related PTSD. Predictors of poorer treatment outcome include greater symptom severity at baseline, comorbid substance use, traumatic brain injury, ongoing trauma exposure, and limited social support.

Long-term follow-up studies indicate that even among treatment responders, relapse rates range from 15-30% over subsequent years, underscoring the importance of maintenance strategies and long-term follow-up. Early intervention within the first months following trauma exposure is associated with better long-term outcomes.

10. Prevention

Psychological first aid (PFA) — immediate post-trauma support emphasizing safety, calming, self-efficacy, social connectedness, and hope; recommended over psychological debriefing
Critical incident stress management — organizational frameworks for post-incident support in high-risk professions
Early brief cognitive-behavioral interventions — 4-5 sessions of trauma-focused CBT within weeks of trauma exposure for individuals showing acute stress symptoms
Screening and monitoring — systematic screening of at-risk populations (military, first responders, trauma survivors) to enable early identification
Social support mobilization — facilitating connection with family, peers, and community resources post-trauma
Pre-deployment resilience training — programs such as the U.S. Army's Comprehensive Soldier Fitness targeting stress inoculation and coping skills before trauma exposure
Pharmacological prevention — hydrocortisone administration in the acute aftermath of trauma shows modest preventive effects in some studies; propranolol for memory reconsolidation blockade remains experimental
Note: Single-session psychological debriefing (Critical Incident Stress Debriefing) is not recommended and may paradoxically increase PTSD risk

11. Recent Research and Advances

MDMA-assisted psychotherapy represents one of the most significant recent advances in PTSD treatment. Phase III clinical trials demonstrated that MDMA-assisted therapy achieved a 71% response rate and 33% complete remission rate versus 48% response and 5% remission for placebo plus therapy. MDMA is proposed to facilitate trauma processing by reducing fear responses, enhancing therapeutic alliance, and promoting emotional engagement. The FDA reviewed the New Drug Application with advisory committee proceedings in 2024, marking a potential paradigm shift in treatment-resistant PTSD management.

Psilocybin-assisted therapy is being investigated in early-phase trials for PTSD, with preliminary evidence suggesting it may facilitate emotional processing and cognitive flexibility through 5-HT2A receptor agonism and enhanced neuroplasticity. Several Phase II trials are underway as of 2025-2026.

Ketamine and esketamine have shown rapid-onset antidepressant and anti-PTSD effects through NMDA receptor antagonism and enhanced synaptic plasticity. Repeated intravenous ketamine infusions (0.5 mg/kg over 40 minutes) have demonstrated significant symptom reduction in treatment-resistant PTSD within hours to days.

Digital therapeutics are expanding access to evidence-based care. The VA's PTSD Coach and CPT Coach mobile applications, along with internet-delivered prolonged exposure and cognitive processing therapy programs, have shown promising efficacy in randomized trials. Artificial intelligence-driven tools for early PTSD detection through voice analysis, digital phenotyping, and natural language processing are in active development.

Neurobiological biomarkers research is advancing toward precision medicine approaches. Blood-based biomarkers including cortisol reactivity profiles, inflammatory markers (CRP, IL-6, TNF-alpha), and epigenetic signatures (FKBP5 methylation) are being validated for predicting PTSD risk and treatment response. Neuroimaging biomarkers, including amygdala-prefrontal connectivity patterns, may enable treatment matching in the future.

12. References & Research

Historical Background

Descriptions of trauma-related psychological disturbance have appeared throughout recorded history, from ancient Mesopotamian texts to accounts of "soldier's heart" during the American Civil War and "shell shock" during World War I. The modern understanding of PTSD was shaped by Abram Kardiner's work on "traumatic neuroses of war" (1941) and the systematic study of Vietnam War veterans led by Chaim Shatan and Robert Jay Lifton in the 1970s. PTSD was formally codified as a diagnosis in DSM-III (1980), with Judith Herman's landmark book Trauma and Recovery (1992) broadening the conceptual framework to include interpersonal trauma and complex PTSD. The diagnosis underwent significant revision in DSM-5 (2013), adding the dissociative subtype and moving PTSD out of the anxiety disorders category.

Key Research Papers

Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. DOI: 10.1001/archpsyc.62.6.593
Yehuda R, Hoge CW, McFarlane AC, et al. Post-traumatic stress disorder. Nat Rev Dis Primers. 2015;1:15057. DOI: 10.1038/nrdp.2015.57
Milad MR, Pitman RK, Ellis CB, et al. Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol Psychiatry. 2009;66(12):1075-1082. DOI: 10.1016/j.biopsych.2009.06.026
Rauch SL, Shin LM, Phelps EA. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research. Biol Psychiatry. 2006;60(4):376-382. DOI: 10.1016/j.biopsych.2006.06.004
Foa EB, Hembree EA, Cahill SP, et al. Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring. J Consult Clin Psychol. 2005;73(5):953-964. DOI: 10.1037/0022-006X.73.5.953
Resick PA, Nishith P, Weaver TL, et al. A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol. 2002;70(4):867-879. DOI: 10.1037/0022-006X.70.4.867
Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. DOI: 10.1038/s41591-021-01336-3
Bisson JI, Roberts NP, Andrew M, et al. Psychological therapies for chronic post-traumatic stress disorder (PTSD) in adults. Cochrane Database Syst Rev. 2013;(12):CD003388. DOI: 10.1002/14651858.CD003388.pub4
Lehrner A, Yehuda R. Biomarkers of PTSD: military applications and considerations. Eur J Psychotraumatol. 2014;5:23797. DOI: 10.3402/ejpt.v5.23797
Shalev AY, Ankri Y, Israeli-Shalev Y, et al. Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem Trauma Outreach and Prevention Study (J-TOPS). Arch Gen Psychiatry. 2012;69(2):166-176. DOI: 10.1001/archgenpsychiatry.2011.127
Hoge CW, Castro CA, Messer SC, et al. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004;351(1):13-22. DOI: 10.1056/NEJMoa040603
Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2006;(1):CD002795. DOI: 10.1002/14651858.CD002795.pub2
Nievergelt CM, Maihofer AX, Klengel T, et al. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat Commun. 2019;10(1):4558. DOI: 10.1038/s41467-019-12576-w
Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-688. DOI: 10.1001/jamapsychiatry.2014.62